Anesthesiology Department, Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, USA.
Department Internal Medicine I, Klinikum Saarbrücken, Saarbrücken, Germany.
Curr Rheumatol Rep. 2022 Jul;24(7):238-246. doi: 10.1007/s11926-022-01077-3. Epub 2022 May 3.
This review will address the many uncertainties surrounding the medical use of cannabidiol (CBD). We will begin with an overview of the legal and commercial environment, examine recent preclinical and clinical evidence on CBD, explore questions concerning CBD raised by healthcare professionals and patients, investigate dosing regimens and methods of administration, and address current challenges in the accumulation of sound evidence.
CBD has potential for relief of symptoms of pain, sleep, and mood disturbance in rheumatology patients, but sound clinical evidence is lacking. CBD is safe when accessed from a regulated source, whereas wellness products are less reliable regarding content and contaminants. Dosing for symptom relief has not yet been established. As many rheumatology patients are trying CBD as a self-management strategy, the healthcare community must urgently accrue sound evidence for effect.
本篇综述旨在解决围绕医用大麻二酚（CBD）使用的诸多不确定性。我们将首先概述法律和商业环境，接着探讨 CBD 的最新临床前和临床证据，研究医疗保健专业人员和患者对 CBD 提出的问题，调查给药方案和管理方法，并解决目前在积累可靠证据方面的挑战。
CBD 可能缓解风湿患者的疼痛、睡眠和情绪障碍症状，但缺乏可靠的临床证据。从监管渠道获取 CBD 是安全的，而保健产品在含量和污染物方面则不太可靠。缓解症状的剂量尚未确定。由于许多风湿病患者正在将 CBD 作为自我管理策略，医疗保健界必须紧急积累有关疗效的可靠证据。
